CHARLOTTESVILLE, Virginia, November 9, 2010 /PRNewswire/ — Biovista announced today that it has entered into a pilot research collaboration agreement with Pfizer (Pfizer Inc. (NYSE: PFE). The aim of the collaboration is to identify new indications for a number of undisclosed Pfizer development candidates, using Biovista’s Clinical Outcome Search Space (COSS) technology. Under the terms … Read More
News
Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
CHARLOTTESVILLE, Virginia, July 13, 2010 /PRNewswire/ — Biovista announced today the appointment of Mr. Clifford H. Farrah, President and Chairman of The Beacon Group, to its Advisory Board. “We are very excited to have Cliff join our Advisory Board,” said Aris Persidis, President of Biovista. “Cliff brings a wealth of direct commercial development experience in … Read More
Biovista Featured in CHI’s InsightPharma Report on Drug Repositioning
Biovista Inc., Charlottesville, July 7, 2010: Biovista today announced that it is a featured company in InsightPharma’s report on Drug Repositioning. The report “Drug Repositioning: Extracting Added Value from Prior R&D Investments” by Dr. Hermann A.M. Mucke explains the basic issues surrounding drug repositioning as a pipeline development and/or lice cycle management strategy, covers the … Read More
Biovista to present at the 8th Int’l Conference on Pathways, Networks, and Systems Medicine
Biovista Inc., Charlottesville, July 7, 2010: Biovista today announced that it will be presenting at the 8th International Conference on Pathways, Networks, and Systems Medicine to be held at the Sheraton rhodes hotel in Rhodes, July 9 – 14, 2010. Dr Andreas Persidis, CEO of Biovista Inc. will present on Sunday 11 July, 11:45am local … Read More
Drug Repositioning: Extracting Added Value from Prior R&D Investments
Biovista profiled in latest Insight Pharma report “Drug Repositioning:Extracting Added Value from Prior R&D Investments”. Drug repositioning is also known as drug repurposing, reprofiling, or retasking. In “on-target repurposing,” a drug’s known pharmacological mechanism is applied to a different therapeutic indication than that for which it was initially developed. Even more innovative is “off-target repurposing, ” … Read More